Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.720 +0.160 (+2.44%)
Official Closing Price Updated: 8:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics 
Via Benzinga
Exposures Product Safety
Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules
Cybin Inc. (NYSE:CYBN) a company developing novel psychedeli... 
Via Benzinga
Cybin Inc. Receives Schedule I Manufacturing License from DEA
Cybin (NYSE: 
Via Benzinga
Cybin Inc. Schedules R&D Briefing to Release Breakthrough Research Findings
Cybin (NEO: CYBN) (NYSE: 
Via Benzinga
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
This Psychedelics Stock Could Grow 300% In One Year
Cantor Fitzgerald initiated coverage of Cybin (NYSE: 
Via Benzinga
Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex
Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)... 
Via Benzinga
Exposures Product Safety
Cybin Inc. Announces FDA IND Authorization of Potentially Pivotal Study
Cybin (NYSE: 
Via Benzinga
Exposures Product Safety
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
The Week In Psychedelics 
Via Benzinga
Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up?
The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last. 
Via Talk Markets
Psychedelics Discussed At Benzinga Cannabis Capital Conference: Growth Opportunities, Mental Health & Pharma
Ronan Levy, co-founder and executive chairman of Field Trip Ltd (NASDAQ: FTRP), a company developing a network of psychedelics-assisted therapy clinics; Doug Drysdale, CEO,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
6 Psychedelic Stocks With Buy Rating: Why Are They Good Investments?
This article by Jason Najum was originally published on 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Four Stocks Disrupting Mental Health To Keep An Eye On At Benzinga's Healthcare Conference
The healthcare sector is booming and startups are the driving force behind the innovations that will affect the future of life on earth. ... 
Via Benzinga
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio?
We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ: 
Via Benzinga
Cannabis Drug Stocks Have Mirrored Performance Of Psychedelic Drug Stocks To Date In September
Which index has outperformed so far in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index? 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
38 Stocks Moving In Thursday's Mid-Day Session
Gainers IronNet Cybersecurity, Inc. (NASDAQ: IRNT) shares jumped 30.4% to $41.90 amid increased retail investor interest in the stock on social media. Dutch Bros Inc. (NYSE: BROS... 
Via Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
Marijuana Vs. Psychedelic Drug Stocks: Which Out-Performed Last Week?
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 8 constituents in each of two sub-categories, let's see which out-performed last week. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Buying Cybin Stock Right Now Could Be a Brilliant Move
You'll need to be prepared for a long holding period and a hearty helping of risk. 
Via The Motley Fool
Topics Law Enforcement
Exposures Legal
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
48 Biggest Movers From Yesterday
Gainers RenovoRx, Inc. (NASDAQ: RNXT) climbed 107.8% to close at $16.02 on Monday after the company was granted FDA clearance for ‘Catheter, Intravascular Occluding,... 
Via Benzinga
Exposures Product Safety
35 Stocks Moving In Monday's Mid-Day Session
Gainers Globalstar, Inc. (NYSE: GSAT) shares climbed 43.6% to $2.0535. GSAT shares traded higher following a note sent out by popular Apple Inc. (NASDAQ: AAPL) analyst Ming... 
Via Benzinga
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Contents 
Via Benzinga
Magic Mushroom Drug Stock Performances YTD
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE: 
Via Benzinga
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) Files Two International Patent Applications In Support Of The Company's Research Phase Programs
Cybin (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.